🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

25+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 25 recruiting trials for “Rare hypercholesterolemia

NARecruitingNCT07470723

The ORIGIN-FH Study

👨‍⚕️ Amy Peterson, MD, MS, University of Wisconsin, Madison📍 1 site📅 Started Feb 2026View details ↗
NARecruitingNCT06960902

Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)

👨‍⚕️ Bertrand CARIOU, Pr📍 9 sites📅 Started Sep 2025View details ↗
Phase 2, PHASE3RecruitingNCT07058077

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

👨‍⚕️ Medical Director, Merck Sharp & Dohme LLC📍 21 sites📅 Started Aug 2025View details ↗
RecruitingNCT06958315

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

🏥 Novartis Pharmaceuticals📍 19 sites📅 Started Jun 2025View details ↗
RecruitingNCT04529967

Child-Parent Familial Hypercholesterolemia Screening

👨‍⚕️ LIling Qian, Master, Children's Hospital of Fudan University📍 6 sites📅 Started Apr 2025View details ↗
Phase 3RecruitingNCT06597006

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 18 sites📅 Started Feb 2025View details ↗
RecruitingNCT06634160

Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia

🏥 Nantes University Hospital📍 3 sites📅 Started Jan 2025View details ↗
Phase 3RecruitingNCT06597019

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 66 sites📅 Started Dec 2024View details ↗
NARecruitingNCT06331195

An Adapted Brazilian Cardioprotective Diet, Phytosterols and Krill Oil in Familial Hypercholesterolemia (DICA-FH)

👨‍⚕️ Aline Marcadenti, PhD, Hospital do Coracao📍 24 sites📅 Started Oct 2024View details ↗
NARecruitingNCT06439654

Atlantic Lipid Lowering Treatment Optimization Program

👨‍⚕️ Robert D Fishberg, MD, Atlantic Health System📍 2 sites📅 Started Jul 2024View details ↗
Enrolling by InvitationNCT06112327

Long-term Follow-up of Participants Dosed with an Investigational Gene Editing Therapy for Cardiovascular Disease

🏥 Verve Therapeutics, Inc.📍 3 sites📅 Started Jun 2024View details ↗
Phase 1RecruitingNCT06164730

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

🏥 Verve Therapeutics, Inc.📍 21 sites📅 Started Apr 2024View details ↗
EARLY_Phase 1RecruitingNCT06461702

Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)

🏥 The First Affiliated Hospital of Bengbu Medical University📍 1 site📅 Started Apr 2024View details ↗
Phase 2RecruitingNCT04941599

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

👨‍⚕️ MacRae F. Linton, MD, Vanderbilt University Medical Center📍 1 site📅 Started Feb 2024View details ↗
NARecruitingNCT05614219

Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.

👨‍⚕️ Finn Lund Henriksen, Ph.d., Departement of Cardiology, Odense University Hospital📍 2 sites📅 Started Dec 2023View details ↗
NAEnrolling by InvitationNCT05750667

Penn Family Screening for Familial Hypercholesterolemia

🏥 Northwestern University📍 1 site📅 Started Jan 2023View details ↗
NAEnrolling by InvitationNCT05284513

Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)

👨‍⚕️ Laney K Jones, PharmD, MPH, Geisinger Clinic📍 1 site📅 Started Sep 2022View details ↗
NAEnrolling by InvitationNCT05746247

Improving Diagnosis and Clinical Management of Familial Hypercholesterolemia Through Integrated Machine Learning, Implementation Science, and Behavioral Economics

🏥 University of Pennsylvania📍 1 site📅 Started Mar 2022View details ↗
Enrolling by InvitationNCT04929457

Evaluation of a Digiphysical Screening Method to Identify and Diagnose Familial Hypercholesterolemia

👨‍⚕️ Jonas Brinck, MD PhD, Dept. of Medicine Huddinge H7, Karolinska Institute, Stockholm📍 1 site📅 Started Sep 2021View details ↗
Phase 3Enrolling by InvitationNCT04798430

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

👨‍⚕️ David Kallend, MB BCh, LIB Therapeutics📍 12 sites📅 Started Dec 2020View details ↗
Page 1 of 2Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →